Science Current Events | Science News |

Drug combination may provide option to patients with NSCLC ineligible for bevacizumab

April 03, 2012
CHICAGO - A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

"The combination of carboplatin and nab-paclitaxel demonstrates promising efficacy with tolerable toxicity in patients with non-small cell lung cancer (NSCLC) ineligible for therapy with bevacizumab," said Gregory A. Otterson, M.D., professor of internal medicine, co-director of the thoracic oncology program and associate director of the hematology and medical oncology fellowship program at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio.

Otterson and colleagues evaluated the drug combination in 63 patients with advanced NSCLC. Seventy-six percent of patients had squamous histology, making them ineligible for bevacizumab. Other contraindications for bevacizumab among this patient population included hemoptysis, thrombosis and therapeutic anticoagulation. Researchers assigned patients to 300 mg/m2/AUC6, which was later adjusted to 260 mg/m2/AUC6 due to excess neuropathy, every 21 days.

Researchers found an overall response rate of 41 percent among 53 patients available for evaluation. An additional 39 percent of patients had stable disease for at least six weeks. Disease progressed in 19 percent of patients.

"We have been surprised at the durability of response with some patients not requiring further treatment for at least six months," Otterson said.

More than 10 percent of patients had grade 3 to 4 toxicities, including hematologic toxicity, febrile neutropenia, infection, sensory neuropathy, dyspnea and dehydration; researchers reported four deaths as grade 5 toxicities. "This combination treatment should be an option, particularly for patients with squamous histology who have limited alternative options," Otterson said.

American Association for Cancer Research

Related Bevacizumab Current Events and Bevacizumab News Articles

Biomarker may predict who'll benefit from targeted therapy for HER2-negative breast cancer
A multicenter team led by Case Western Reserve has demonstrated that brief exposure to a targeted therapy can tell doctors which HER2-negative patients will respond -- and which should switch to another kind of treatment.

Fears of potentially blinding complication from Avastin eye injections overblown, says Penn study
Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug Lucentis made by the same company, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

Thin colorectal cancer patients have shorter survival than obese patients
Although being overweight with a high body-mass index (BMI) has long been associated with a higher risk for colorectal cancer, thinner patients might not fare as well after treatment for advanced cancer, according to a new study from Duke Medicine.

Mayo Clinic study suggests which glioblastoma patients may benefit from drug treatment
Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit.

Development of new blood vessels not essential to growth of lymph node metastases
While the use of antiangiogenesis drugs that block the growth of new blood vessels can improve the treatment of some cancers, clinical trials of their ability to prevent the development of new metastases have failed.

Study suggests new way of preventing diabetes-associated blindness
Reporting on their study with lab-grown human cells, researchers at The Johns Hopkins University and the University of Maryland say that blocking a second blood vessel growth protein, along with one that is already well-known, could offer a new way to treat and prevent a blinding eye disease caused by diabetes.

TGen-UCSF study in Neuro-Oncology provides comprehensive look at brain cancer treatments
Led by the Translational Genomics Research Institute (TGen) and UC San Francisco (UCSF), a comprehensive genetic review of treatment strategies for glioblastoma brain tumors was published today in the Oxford University Press journal Neuro-Oncology.

Allow NHS doctors to prescribe cheap, safe and effective sight loss drug, says The BMJ
NHS doctors should be allowed to prescribe a cheap, safe and effective drug for the degenerative eye disease, wet age related macular degeneration (AMD) - a leading cause of blindness among older patients, says an investigation by The BMJ today.

Tumor location in colorectal cancer may influence survival
The two halves of the human colon have different embryonic origins and gene expression patterns, and these differences may also play a role in cancer biology, according to a study published February 24 in the JNCI: Journal of the National Cancer Institute.

Breast Cancer Specialist Presents Positive Results for Triple-Negative Breast Cancer Presurgery Chemotherapy Benefits
A breast cancer specialist and clinical researcher at Women & Infants Hospital of Rhode Island presented research yesterday at the 2014 San Antonio Breast Cancer Symposium showing that adding either the chemotherapy drug carboplatin or the blood vessel-targeting drug bevacizumab to the standard treatment of chemotherapy before surgery helped women who have the basal-like subtype of triple-negative breast cancer.
More Bevacizumab Current Events and Bevacizumab News Articles

Hemophilia and Hemostasis: A Case-Based Approach to Management

Hemophilia and Hemostasis: A Case-Based Approach to Management
by Alice D. Ma (Editor), Harold R. Roberts (Editor), Miguel A. Escobar (Editor)

There is a general need amongst healthcare professionals for practical advice on the management of patients with bleeding disorders. This book is an essential resource for all those working in the fields of coagulation, hemostasis and thrombosis. It covers the major cases one might encounter in diagnosing, managing and treating hemophilia and hemostasis. It provides a practical and informative guide to the broad range of topics concerning both bleeding and clotting disorders.  The book is divided into major chapter sections depending on the type of bleeding disorder it fits into. Each chapter includes a brief overview of the disorder covering: history of the disorder; molecular basis of the disorder; class presentation; genetics; current laboratory tests and monitoring. Cases associated...

2010 Oncology Nursing Drug Handbook

2010 Oncology Nursing Drug Handbook
by Gail Wilkes (Author), Margaret Barton-Burke (Author)

Written expressly for nurses caring for patients with cancer, the 2010 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. An essential reference updated annually, the text provides valuable information on effective symptom management, patient education, and chemotherapy administration. Completely revised and updated, the 2010 Oncology Nursing Drug Handbook includes: New and updated administered drugs. Specific drugs are described in terms of their mechanism of action, metabolism, drug interactions, laboratory effects/interference, and special considerations. The most important and common drug side effects are discussed.

AVASTIN (Bevacizumab): Treats Cancer, including Colorectal, Lung, Glioblastoma, Kidney, Cervical, and Ovarian Cancer

AVASTIN (Bevacizumab): Treats Cancer, including Colorectal, Lung, Glioblastoma, Kidney, Cervical, and Ovarian Cancer
by James Lee Anderson (Author)

“Although, your health condition may impact your everyday life, do not let it define who you are.” AVASTIN (Bevacizumab) injection is given with other medicines to treat patients with metastatic (a cancer that has spread) carcinoma of the colon or rectum. This medicine is also used to treat a certain type of metastatic lung cancer called nonsquamous, non-small cell lung cancer, and a certain type of brain tumor called glioblastoma. AVASTIN (Bevacizumab) is a substance that helps the body fight cancer. It prevents the growth of certain types of blood vessels to cancer cells. This helps to decrease the growth of cancer cells by starving the cells of nutrients that are needed to grow. AVASTIN (Bevacizumab) injection is also used in combination with other medicines (eg, interferon alfa)...

Handbook of Therapeutic Antibodies

Handbook of Therapeutic Antibodies
by Stefan Dübel (Editor), Janice M. Reichert (Editor)

Still the most comprehensive reference source on the development, production and therapeutic application of antibodies, this second edition is thoroughly updated and now has 30% more content.

Volume 1 covers selection and engineering strategies for new antibodies, while the second volume presents novel therapeutic concepts and antibodies in clinical study, as well as their potential. Volumes 3 and 4 feature detailed and specific information about each antibody approved for therapeutic purposes, including clinical data. This unique handbook concludes with a compendium of marketed monoclonal antibodies and an extensive index.

Beyond providing current knowledge, the authors discuss emerging technologies, future developments, and intellectual property issues, such that...

Smart Infusion Pumps: Implementation, Management, and Drug Libraries

Smart Infusion Pumps: Implementation, Management, and Drug Libraries
by Pamela K. Phelps PharmD FASHP (Editor)

The pumps are smart. The book is brilliant.Purchasing intelligent infusion devices can be a complicated and costly endeavor. ASHP is proud to offer the first book devoted to the implementation and management of intelligent infusion devices. Smart Infusion Pumps: Implementation, Management, and Drug Libraries, is an indispensable reference for hospitals and health-systems that are either currently using “intelligent infusion device” technology, or are considering implementation.Inside you’ll find An introduction to smart infusion pump technology A guide to choosing a pump, developing RFPs, and usability testing Guiding principles for implementation of smart infusion pumps Techniques for developing dosing limits for medications “Practice Tips” for implementation and...

Complications of Glaucoma Surgery

Complications of Glaucoma Surgery
by Robert M. Feldman (Editor), Nicholas P. Bell (Editor)

Glaucoma surgery is difficult and fraught with complications. Some complications are common and mild, while others are rare and/or vision threatening. However, good outcomes are still likely if those complications encountered are managed properly.

This book is intended for those surgeons wishing to improve their skills and abilities to manage difficult problems that will come up during the care of glaucoma patients. Comprising seven comprehensive sections, chapters in this volume address outflow mechanisms after glaucoma surgery, wound healing processes and modulators, complications in filtering surgery, tube shunt implantation, and angle procedures, among other topics. The authors of each chapter provide surgical and clinical pearls not only for managing difficulties but in...

Gynecologic Oncology Handbook: An Evidence-Based Clinical Guide

Gynecologic Oncology Handbook: An Evidence-Based Clinical Guide
by Michelle Benoit MD (Author), M. Yvette Williams-Brown MD (Author), Creighton Edwards MD (Author)

"Gynecologic Oncology Handbook provides a comprehensive yet concise, practical guide for fellows, residents, specialist trainees, and clinicians in the diagnosis and management of gynecologic cancers. The book addresses the fundamentals of gynecologic oncology, including staging, surgical therapies, comorbidity diagnosis and management, adjuvant therapies including chemotherapy and radiation, and survival and palliative care. With a focus on specific management decision-making, the book provides the basic information needed to guide the clinician on the ward or in the clinic, including clinical study references, medical comorbidity algorithms, and directed gynecologic cancer workups and treatments. In a bullet point format, the book provides the resources you need to meet the demands of...


by Roger J. Packer (Editor), David Schiff (Editor)

Cancer imposes daunting effects on the nervous system Brain cancer is one of the most devastating diagnoses a physician can deliver. Cancer of the nervous system can take many different forms. Treatment is specific to the type of malignancy, its location in the nervous system and, increasingly, its molecular characteristics. The challenges manifest further when management choices need to be made, and multidisciplinary approaches are required. Additional complexities arise in children, where the developing neurological system requires more sensitive treatment. Neuro-oncology unmasks the complexities to provide a straightforward guide to cancers of the nervous system. Following a general approach to diagnosis and treatment, the clinical aspects of specific cancer types in adults and...

Cardiac Management of Oncology Patients: Clinical Handbook for Cardio-Oncology

Cardiac Management of Oncology Patients: Clinical Handbook for Cardio-Oncology
by Gonzalo Baron Esquivias (Editor), Riccardo Asteggiano (Editor)

This book is designed for clinical cardiologists and other physicians working with cardiac patients, where specific specialized teams of cardio-oncologists are not available and who are called to perform a clinical consultation to evaluate both the cardiac condition and the eligibility for chemotherapy or radiotherapy treatment, and to evaluate if a cancer treatment produces toxic effects on a patient treated with chemo or radiotherapy and if appearance of new symptoms is due to this treatment. In recent years, progress in oncologic therapy has resulted in important developments and the prognostic improvement of patients with malignancy. The cornerstone of chemotherapy are the anthracyclines (and the analogue Mitoxantrone), that are direct cellular toxic agents and that are among the most...

Managing Diabetic Eye Disease in Clinical Practice

Managing Diabetic Eye Disease in Clinical Practice
by Rishi Singh (Editor)

This handbook is an overview of the diagnosis, treatment and long-term management of diabetic retinopathy, within the context of overall long-term diabetes disease management. Diabetes-related eye damage (diabetic retinopathy) is one of the most common complications of diabetes, affecting approximately 30-40% of people with diabetes. The situation is so severe that in countries such as the US and UK, diabetic retinopathy is currently the leading cause of blindness in people age 20 to 74 years old. Fortunately, there are several existing and emerging treatments on the horizon and with adequate control of the underlying diabetes, this condition can be successfully managed.

© 2015